<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04952922</url>
  </required_header>
  <id_info>
    <org_study_id>CCR5242</org_study_id>
    <nct_id>NCT04952922</nct_id>
  </id_info>
  <brief_title>Changes to Function and Quality of Life and Patient Experience for Patients Undergoing Treatments for Recurrent Oropharyngeal Cancer</brief_title>
  <acronym>FUNQOLR</acronym>
  <official_title>Changes to Function and Quality of Life and Patient Experience for Patients Undergoing Treatments for Recurrent Oropharyngeal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Marsden NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research project is to measure changes in communication, swallowing and&#xD;
      quality of life and individual patient priorities which may happen over time in patients with&#xD;
      a diagnosis of recurrent head and neck cancer, specifically recurrent cancer (cancer which&#xD;
      has returned after previous treatment) of the back of the throat, the tonsils and/or the base&#xD;
      of tongue (recurrent oropharyngeal cancer) and what it is like for patients and their&#xD;
      significant others to experience these changes over time.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patient reported swallowing related quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>MD Anderson Dysphagia Inventory</description>
  </primary_outcome>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Recurrent Oropharynx Carcinoma</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Treatment for recurrent oropharyngeal cancer (curative/ palliative)</intervention_name>
    <description>Open salvage surgery, transoral robotic surgery, palliative chemotherapy, immunotherapy.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a confirmed diagnosis of recurrent, residual or new primary oropharyneal&#xD;
        cancer in a previously irradiated field.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult (aged 18 years or over) competent to provide consent&#xD;
&#xD;
          -  Have a diagnosis of recurrent OPC&#xD;
&#xD;
          -  Have adequate linguistic and cognitive function to participate in interview&#xD;
&#xD;
          -  English speaking&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any previous medical condition, other than HNC, which has a known impact on&#xD;
             communication/ swallowing (Parkinson's Disease, Multiple Sclerosis, cerebral vascular&#xD;
             accident (CVA)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 28, 2021</study_first_submitted>
  <study_first_submitted_qc>June 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

